肺高血压的临床-放射学-病理相关性与不清楚的和/或多因素机制
Mona Lichtblau1, Laura Mayer1, Deepa Gopalan2,3
1University and University Hospital of Zurich, Zurich, Switzerland.
概括
肺高血压 (PH) 第5组包括各种各样的疾病,其原因复杂,由于研究有限,造成管理挑战. 了解这些罕见的PH类型对于患者护理至关重要.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 内部医学 内部医学
背景情况:
- 自1998年埃维安世界研讨会以来,肺高血压 (PH) 被分为五组.
- 第5组PH包括各种疾病,原因不明或多因素.
- 由于患者数量少,表现多样化,研究有限,管理很困难.
研究的目的:
- 审查第5组肺高血压的分类和特征.
- 要突出管理5组PH患者的挑战.
- 为了强调5组PH的重要性,尽管研究有限.
主要方法:
- 审查现有的文献,病例系列和关于第5组PH的注册报告.
- 分析5组PH内子组的分析.
- 讨论临床影响和管理挑战.
主要成果:
- 第5组PH包括六个子组:血液学,系统性,代谢障碍,慢性功能衰竭,肺瘤血栓性微血管病变和纤维化中炎.
- 相关疾病的患病率表明,5组PH的全球负担很大.
- 由于缺乏广泛的研究,因此需要依赖病例报告和登记册.
结论:
- 第5组PH代表了需要专门关注的异质状况的集合.
- 需要进一步的研究和临床试验,以提高对第5组PH的理解和管理.
- 尽管个体疾病很罕见,但5组PH的集体影响是巨大的.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
188
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
188
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
COPD: Pathogenesis and Clinical Features
283
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
283
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
171
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
171


